Offered by: Nemours
Location: Delaware Valley
Efficacy and Safety of Once-Weekly Growth Hormone Compared to Daily Growth Hormone Treatment
What is the trial about?
We want to do this study to learn more about the effectiveness, safety and treatment satisfaction of a once-weekly growth hormone treatment in children with growth hormone deficiency, compared with once daily human growth hormone treatment.
Who can participate?
Children with growth hormone deficiency aged 2-10 years, who have not started puberty and who are about to start treatment with growth hormone injections can be in the study.
What is involved?
In this study, your child will receive either the study drug given once weekly or Norditropin® FlexPro®, given daily. Your child’s participation in the study will last about 157 weeks (36 months and one week). Frequency of visits will occur approximately every one to three months.
There will be 16 blood draws (one per visit), four X-rays and four ECGs throughout the study.
Contact Nemours Clinical Trials
Trial Name: Efficacy and Safety of Once-Weekly Growth Hormone Compared to Daily Growth Hormone Treatment